GSM5359409
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.560
- TNFA_SIGNALING_VIA_NFKB+0.560
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.510
- IL6_JAK_STAT3_SIGNALING+0.510
- ALLOGRAFT_REJECTION+0.500
- INTERFERON_GAMMA_RESPONSE+0.490
- COAGULATION+0.480
- COMPLEMENT+0.470
- INTERFERON_ALPHA_RESPONSE+0.470
- ANGIOGENESIS+0.430
Top 10 suppressed
- E2F_TARGETS-0.640
- G2M_CHECKPOINT-0.580
- MYC_TARGETS_V1-0.520
- MYC_TARGETS_V2-0.350
- MITOTIC_SPINDLE-0.300
- DNA_REPAIR-0.280
- SPERMATOGENESIS-0.260
- MTORC1_SIGNALING-0.200
- UNFOLDED_PROTEIN_RESPONSE-0.140
- GLYCOLYSIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_Z0AVVB1V | pilocytic astrocytoma | — | 0.942 |
| 2 | SRR1797296 | — | cohortMD2 | 0.932 |
| 3 | BS_ZV9Z3SY6 | pilocytic astrocytoma | — | 0.932 |
| 4 | BS_RRAEQZ97 | pilocytic astrocytoma | — | 0.932 |
| 5 | BS_KXH37MPN | DNET | — | 0.929 |
| 6 | BS_AP0SZ364 | low-grade glioma | — | 0.927 |
| 7 | SRR8518191 | — | D | 0.927 |
| 8 | BS_MF9X3PKH | low-grade glioma | — | 0.926 |
| 9 | TCGA-A2-A0EN-01A-13R-A084-07 | — | A | 0.925 |
| 10 | BS_EFEZB0ZH | low-grade glioma | — | 0.924 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.560 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.560 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.510 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.510 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| COAGULATION | 0.480 | Binimetinib | — uncovered |
| COMPLEMENT | 0.470 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.420 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.390 | Inavolisib | — uncovered |
| APOPTOSIS | 0.350 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.280 | Inavolisib | — uncovered |